Drug Profile
Research programme: bispecific antibody therapeutics - Genmab/Kyowa Kirin
Latest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Genmab
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Denmark (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Denmark (Parenteral)
- 05 Dec 2012 Early research in Autoimmune disorders in Denmark (Parenteral)